Integration of Excipients into the Design of Experiments for Pharmaceutical Product and Design Space Development Chris Moreton, Ph.D. FinnBrit Consulting.

Slides:



Advertisements
Similar presentations
The voice of the European food and drink industry Helmut Guenther Coffee and Coffee Substitutes.
Advertisements

Dr. Birgit Schmauser, BfArM, Bonn
Stability Studies - Evaluation of Outcomes and Development of Documentation For Regulatory Submissions Bob Seevers.
Current Statistical Issues in Dissolution Profile Comparisons
Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines / October |1 | Training Workshop on Pharmaceutical Development.
Atypical Actives PDA-FDA Conference March 9-10, 2011 David R. Schoneker
1 Implementation of Quality by Design (QbD): Status, Challenges and Next Steps Moheb M. Nasr, Ph.D. Office of New Drug Quality Assessment (ONDQA), OPS,
Integrating CMC Review & Inspection Industry Recommendations Joe Anisko April 24, 2003.
World Health Organization
Determine impurity level in relevant batches1
VALIDATION OF RAW MATERIALS
MIT PHARMACEUTICAL MANUFACTURING INITIATIVE (PHARMI) PHARMACEUTICAL MANUFACTURING: NEW TECHNOLOGY OPPORTUNITIES.. G.K.Raju, Ph.D. Executive Director, Pharmaceutical.
QUALITY CONTROL OF PHYSICO-Chemical METHODS Introduction :Validation توثيق المصدوقية.
ONDQA Perspective on Post Approval Changes Eric P. Duffy, PhD Director, Division of Post-Market Evaluation, ONDQA, CDER, FDA Public Meeting: Supplements.
Codex Guidelines for the Application of HACCP
B. Neidhart, W. Wegscheider (Eds.): Quality in Chemical Measurements © Springer-Verlag Berlin Heidelberg 2000 D. RuddThe Importance of “Good” Measurements.
Validation of Analytical Method
Application of the principles of QbD in vaccines production Andrea Pranti.
Achieving and Demonstrating “Quality-by-Design” with Respect to Drug Release/dissolution Performance for Conventional or Immediate Release Solid Oral Dosage.
Accelerated Stability Testing
Quality by Design Application of Pharmaceutical QbD for Enhancement of the Solubility and Dissolution of a Class II BCS Drug using Polymeric Surfactants.
Establishing Drug release/Dissolution Specifications – QBD Approach Moheb M. Nasr, Ph.D. Office of New Drug Quality Assessment (ONDQA), OPS, CDER Advisory.
Excipient QbD Concepts to Enhance the Development of Robust Drug Products Priscilla S. Zawislak Global Regulatory Affairs Manager - Ashland Inc. Chair.
Title: Plan for Approach to the Understanding and Predicting Excipient Properties and Functionality NIPTE - National Institute of Pharmaceutical Technology.
1-7.The ICH Q8 “Minimal Approach” to Pharmaceutical Development
Important informations
1 Regulatory Aspects of Pharmaceutical Excipients PQRI Workshop Nick Buhay Acting Director Division of Manufacturing and Product Quality Office of Compliance.
BNF for children and formulations Ian Costello British National Formulary.
1 An Update on ICH Guideline Q8 – Pharmaceutical Development FDA Advisory Committee for Pharmaceutical Science: 5 Oct 2006 Dr John C Berridge Senior Regulatory.
Stability of FPPs- Conducting, Bracketing, Matrixing Sultan Ghani.
Quality by Design & Question-Based Review: Observations by the Generic Pharmaceutical Industry Advisory Committee for Pharmaceutical Science October 5,
Proposed Gluten Regulations in Argentina Excipient Realities and Global Requirements.
Critical Material Properties for Pharmaceutical Dosage Forms - Industry Perspective Tony Hlinak Abbott Laboratories North Chicago, IL.
Pathogen Reduction Dialogue Panel 3 Microbial Testing for Control Verification Robert L. Buchanan U.S. Food and Drug Administration Center for Food Safety.
Molecule-to-Market-Place Quality
Workshop Session 3 Questions 1 How would a control strategy look different in a traditional submission vs a QbD submission? How would parameters that are.
COMPARABILITY PROTOCOLUPDATE ADVISORY COMMITTEE FOR PHARMACEUTICAL SCIENCE Manufacturing Subcommittee July 20-21, 2004 Stephen Moore, Ph.D. Chemistry Team.
Bioequivalence of Locally Acting Gastrointestinal Drugs: An Overview
Excipient Composition and Performance-Related Properties of Excipients Chris Moreton, Ph.D. FinnBrit Consulting IPEC-Americas FDA Seminar, October 21,
Some Future Developments Brian Carlin, Ph.D FMC Chris Moreton, Ph.D FinnBrit Consulting IPEC-Americas FDA Seminar, October 21,
Satish Mallya January 20-22, |1 | 2-3. Pharmaceutical Development Satish Mallya Quality Workshop, Copenhagen May 18-21, 2014 May 18-21,2014.
Validation Defination Establishing documentary evidence which provides a high degree of assurance that specification process will consistently produce.
Excipient Variability Sources, Importance and Potential Impact Chris Moreton, Ph.D Past Chair IPEC-Americas Partner – FinnBrit Consulting
1 Office of Pharmaceutical Science on Jon Clark FDA/CDER/OPS Associate Director for Policy Development.
General Aspects of Quality assessment of multisource interchangeable medicines Rutendo Kuwana Technical Officer, WHO, Geneva Training workshop: Assessment.
Using Product Development Information to Address the Bioequivalence Challenges of Highly-variable Drugs Lawrence X. Yu, Ph. D. Director for Science Office.
FDA PAT Sub-Committee of Advisory Committee for Pharmaceutical Sciences June 12-13, 2002; Gaithersburg, MD Regulatory Challenges: Post-Approval PAT Applications.
Medicines adherence Implementing NICE guidance 2009 NICE clinical guideline 76.
SEMINAR ON PRESENTED BY BRAHMABHATT BANSARI K. M. PHARM PART DEPARTMENT OF PHARMACEUTICS AND PHARMACEUTICAL TECHNOLGY L. M. COLLEGE OF PHARMACY.
3M Drug Delivery Systems 3 Introduction A combination MDI product has been developed containing two active drug substances (designated as A and B) in solution,
Manufacturing of Materials That Are Useful (Fortunately) As Pharmaceutical Excipients Tim Cabelka – Senior Product Research Chemist, Dow Chemical (Retired)
In vitro - In vivo Correlation
In the name of God. Common Technical Document On Biotech.
HOLD-TIME STUDIES.
Proposal for a Manufacturing Classification System (MCS)
B260: Fundamentals of Nursing
Novel approaches for parenteral protein formulations
An Update on ICH Guideline – Pharmaceutical Development
Quality by design (Qbd)
Enabling direct compaction at high drug loading via dry coating of APIs: Towards a predictive framework Presenter(s): Kuriakose T. Kunnath, NJIT Research.
Pharmaceutical Quality in the 21st Century
Dr. Birgit Schmauser, BfArM, Bonn
Uncontrolled variation is the enemy of quality
WHO Technical Report Series, No. 953, 2009
Implementation of Quality by Design (QbD): Status, Challenges and Next Steps Moheb M. Nasr, Ph.D. Office of New Drug Quality Assessment (ONDQA), OPS, CDER.
Chapter 6 Designing the Marketing Channel.
Quality by Design.
Chapter 6 Designing the Marketing Channel.
Chapter 6 Designing the Marketing Channel.
GL 51 – Statistical evaluation of stability data
Presentation transcript:

Integration of Excipients into the Design of Experiments for Pharmaceutical Product and Design Space Development Chris Moreton, Ph.D. FinnBrit Consulting IPEC-Americas FDA Seminar, October 21,

Presentation Outline Background and Introduction Incorporating excipients into the DoE – Single grade excipients – Multiple grade excipients Examples Conclusions 2

Objective To establish a Design of Experiments, Design Space and Control Strategy that will provide for the manufacture of a robust pharmaceutical product. 3

What is a Robust Formulation? A formulation that is able to accommodate the typical variability seen in: – API – Excipients – Processes Without compromising the manufacture, stability, performance or any other attribute of the product critical to the patient’s care or well being. 4

Product variability Bulk Active Drug Variability Excipients Variability Process Variability Product Variability 5

Design of Experiments Excipients are an important part of any formulation. Excipient variability will therefore be an important part of the Design of Experiments (together with the API and the process) 6

Excipients: a recap Made in large quantities often in dedicated plants/equipment trains. They may be of natural, synthetic or semi-synthetic origin. Excipient manufacturing plants are designed to manufacture the excipient at the center of the range for a given specified parameter (i.e. that is controlled). They are NOT designed to produce material at the extremes of specification. Some excipients are available in more than one grade; others may only be available in a single grade. 7

So how can we incorporate Excipient variability into the DoE? QbD offers easier methods than trying to persuade suppliers to prepare material at the upper and lower limits of specification. The methods available will depend on the nature of the excipient and the type of application (formulation). 8

Determine which excipient parameters are likely to impact product performance Use of prior knowledge and expertise to assess each excipient and which properties may impact product performance: – in product manufacture, – product stability, – and product performance during and after administration to the patient. Analogous to a risk assessment (but with the emphasis on product manufacturing, stability and in vivo performance) But, we need to take the formulation into consideration: – If we are making a powder-filled capsule, do we need to worry about the excipient’s compaction profile? – If we are making a liquid product do we need to worry about tapped density? 9

Options for single grade excipients There is a basic assumption that we can measure the excipient parameters that are likely to influence product performance. – Is this always a valid assumption? – Sometimes not (Unknown Unknowns)! We need ways to simulate the extremes of specification for those parameters assessed as having potential to impact excipient performance in the application (formulation). 10

Options for single grade excipients There are three options relying on physical methods: – Fractionation For example, in the case of particle size, we can take sieve cuts to create extremes of particle size. – Level of incorporation For example, in the case of viscosity, we can add less or more of the excipient to simulate preparation of lots at or outside the limits of specification for the particular parameter and excipient. – Conditioning For example, equilibrating the excipient at higher humidity to increase the moisture content. Changes in, for example, the degree of chemical substitution, are beyond these simple physical changes: – Talk to the excipient manufacturer/supplier. 11

Options for excipients having more than one grade There are some implicit assumptions in the use of this approach: – The differentiation between grades is linked to excipient performance in the particular application Otherwise, why be concerned with it? – The parameter of interest can be measured With sufficient precision Using a method that is relevant to the application – The within grade variability is much less than the variability between grades If it isn’t, then why have a different grade? 12

Options for excipients having more than one grade The options available for a single grade can be used. There are further options which may be more useful: – Evaluate the grades either side of the target grade (bracketing) If there is no effect of grade on the performance of the finished product, then the parameter(s) is (are) not related to product performance, and do not need to be included in the DoE. – If there is an effect of the grade on finished product performance, then blends of grades may be used to simulate excipient at the extremes of specification. – If there is an effect of materials simulating the extremes of specification, then is the formulation viable? Excipient batch (lot) selection is a disaster waiting to happen! – For materials at the extremes of the grade range, bracketing is not possible. Proceed as for single grade excipients at the extreme of specification away from the closest grade. 13

Examples Microcrystalline cellulose Carmellose sodium 14

Main Grades of Microcrystalline Cellulose Grade Size Characteristics PH 101ca. 50 µm PH 102ca. 90 µm PH 103ca. 50 µmMoisture content < 3% PH 105< 20 µm PH 112ca. 90 µmMoisture content < 1.5% PH 113ca. 50 µmMoisture content < 1.5% PH 200ca. 180 µm PH 200 LMca. 180 μmMoisture content < 3% PH 301ca. 50 µmHigher density PH 302ca. 80 µmHigher density Ceolus KG 802ca. 50 µmLower density Ceolus UF 711ca. 50 μmLower density, better flow Ceolus KG 1000ca. 50 μmVery low density 15

Grades of Carmellose Sodium Many grades available Grade differentiation is based on: – Substitution range – Intended use: Food, pharmaceutical, cosmetic or industrial use – Viscosity High, medium or low Viscosity range – Particle size 16

Conclusions Incorporation of excipient variability into the Design of Experiments does not have to be complicated. Manufacture of excipients at the extremes of specification is not necessary. QbD offers better options for both single grade excipients and excipients available in multiple grades. 17